CAS: 131069-91-5; Gadoversetamide

📜维塞胺 以71的收率获得钆8,11-二(羧酸甲基)-14-{2-[(2-甲氧基乙基)氨基]-2-氧代乙基}-6-氧代-2-氧杂-5,8,11,14-四氮杂十六烷-16-酸酯
参考文献: Novel Magnetic Resonance Imaging Agents
标题: Novel Magnetic Resonance Imaging Agents
摘要:(中)新型磁共振成像剂包括与双乙烯三胺五乙酸酰基衍生物("dtpa")或乙二胺四乙酸酰基衍生物("edta")的烷氧基烷基酰胺络合物.这些新型成像剂具有优异的核磁共振成像对比性能和在生理溶液中的高溶解度.一种新型的核磁共振诊断方法涉及向恒温动物注射上述的有效量的复合物,然后将恒温动物暴露于核磁共振成像程序,从而成像恒温动物的至少一部分身体.

专利信息

专利号:US-2022233673-A1
优先权日:2019-06-04
标 题:METHODS OF PRODUCING SHIGA TOXIN B-SUBUNIT (STxB) MONOMERS AND OLIGOMERS, AND USES THEREOF
发明人：BILLET ANNE; SCHMIDT FRÉDÉRIC; JOHANNES LUDGER; SERVENT DENIS; MOURIER GILLES; TARTOUR ÉRIC; KAY MICHAEL; FULCHER JAMES M
权利人:INST CURIE; CENTRE NAT RECH SCIENT; INST NAT SANTE RECH MED; COMMISSARIAT A LENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES CEA; APHP ASSIST PUBLIQUE HOPITAUX DE PARIS; UNIV PARIS; UNIV OF UTAH RESEARCH FOUDATION; UNIV UTAH RES FOUND
摘要:A method of producing a monomer of a Shiga toxin B-subunit (STxB) protein or of a variant thereof by peptide chemical synthesis, as well as to a method of producing a pentamer of the STxB protein or of the variant thereof. The methods are particularly advantageous as they overcome major issues typically observed in peptide chemical synthesis, including solubility and purity issues.

专利号:US-2022118123-A1
优先权日:2019-02-22
标 题 :Combination of ar antagonists and targeted thorium conjugates
发明人：HAMMER STEFANIE; HAGEMANN URS BEAT; HAENDLER BERNARD; LEJEUNE PASCALE; ZITZMANN-KOLBE SABINE; SCHATZ CHRISTOPH; KARLSSON JENNY
权利人:BAYER AG; BAYER AS
摘要:The present invention covers combinations of at least two components, component A and component B, comprising component A being PSMA-TTC, and component B being an antiandrogen selected form AR antagonists such as from cyproterone acetate, bicalutamide, flutamide, nilutamide, enzalutamide, apalutamide, darolutamide or keto-darolutamide, or an AR degrader such as ARV-110, or an ARN-terminal domain binder such as EPI-506, or an antisense oligonucleotide that reduces AR expression such as EZN-4176 or AZD-5312, or an androgen synthesis inhibitor such as abiraterone, particularly abiraterone acetate, seviteronel, galeterone, orteronel or ketoconazole, or a dual AR antagonist and androgen synthesis inhibitor such as ODM-204. Another aspect of the present invention covers the use of such combinations as described herein for the preparation of a medicament for the treatment or prophylaxis of a disease, particularly for the treatment of a hyper-proliferative disease.

专利号:US-2011104052-A1
优先权日:2007-12-03
标 题 :Methods of synthesis and use of chemospheres
发明人：BARNETT BRADLEY POWERS; GESCHWIND JEFFREY
权利人:UNIV JOHNS HOPKINS
摘要:The present invention provides, in general, compositions comprising a hydrogel and an agent, for example a therapeutic agent or an imaging agent, for locoregional delivery. In certain preferred embodiments of the invention, the hydrogel compositions are detectable by Magnetic Responance and CT Scan and are used for locoregional delivery of therapeutic agents, for example chemotherapeutic agents. The invention also features polymer matrix compositions comprising nanoparticles that can be loaded after polymerization with bioactive agents, for example a diagnostic agent or therapeutic agent.

专利号:US-2016138027-A1
优先权日:2013-03-14
标 题:Treatment of diseases and conditions associated with dysregulation of mammalian target of rapamycin complex 1 (mtorc1)
发明人：GAN LIN; MEYER TOBIAS
权利人:UNIV LELAND STANFORD JUNIOR
摘要:Compositions and methods for treating diseases and conditions associated with dysregulation of mammalian target of rapamycin complex 1 (mTORC1) are disclosed. The invention is based in part on the discovery that protein mediator of amino acid signaling to mTOR (MORTOR) is involved in amino acid-induced translocation of mTORC1 to lysosomes where MORTOR forms a signaling complex with mTORC1, Ragulator, and Rag GTPases, which controls protein synthesis. In particular, the invention relates to the use of antagonists of MORTOR for treating diseases and conditions associated with dysregulation of mTORC1. Downregulation of expression of MORTOR by RNA interference has been shown to reduce cell proliferation of cancerous cells and may be useful for treating cancer.

专利号:US-2005033106-A1
优先权日:2003-07-08
标 题 :Synthesis of tris N-alkylated 1,4,7,10-tetraazacyclododecanes

专利号:WO-2005003105-A1
优先权日:2003-07-08
标 题 :Synthesis of tris n-alkylated 1,4,7,10-tetraazacyclododecanes